Shares of Staar Surgical Co. dropped 25% on Feb. 11 after it surprised Wall Street when it reported fourth quarter sales falling 36% to $49 million.Two weeks later, the Lake Forest-based maker of ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition.

Mizuho has downgraded STAAR Surgical (NASDAQ ... The investment bank said the "sharpness of the correction" of China ICL sales in Q4 and "very modest" outlook for the first half of 2025 was ...

Understanding the gray zone can greatly help the accuracy of this important measurement in sizing for the EVO ICL (STAAR Surgical). My preference is a mid-gray zone to mid-gray zone measurement ...

Despite these headwinds, STAAR generated $152 million of ICL sales outside of China, which is growth of 17% and 13% in the fourth quarter and fiscal 2024 respectively. STAAR's double-digit growth ...

Staar Surgical Co (NASDAQ:STAA) reported strong growth in ICL sales outside of China, with a 17% increase in the fourth quarter and 13% for the full year 2024. The company achieved a 22% growth in ...

“There are so many excellent nomograms out there now.” In addition, Hirabayashi offered his own perspective on the ICL (STAAR Surgical) as a low myope himself. Hirabayashi M. Low myopia and ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

We look forward to supporting our customers and patients around the world, as we drive EVO ICL as the first choice for doctors and patients seeking visual freedom. I want to thank the STAAR team ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...